Three abstracts on OXC-101 selected for poster presentations at AACR 2023
Oxcia AB (publ) today reports that three abstracts on OXC-101, its clinical candidate for cancer, have been selected for poster presentations at the American Association for Cancer Research (AACRS) Annual meeting held in Orlando, Florida, 14-19[th] April, 2023 . The abstracts concern the clinical safety, further understanding of the broad anti-cancer efficacy and the mechanism of action and will be published in the online Proceedings supplement of the AACR journal Cancer Research.Many cancers suffer from oxidative stress and high levels of endogenous oxidative DNA damage. The enzyme MTH1